ArticleSchizophrenia research2011
Are we studying and treating schizophrenia correctly?
Article in Schizophrenia research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02634684 (Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis), which is not on this map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Meta-Analysis of Sensorimotor Gating Deficits in Patients With Schizophrenia Evaluated by Prepulse Inhibition Test.Schizophrenia bulletin · 2020Pooled it
- Pharmacologic Augmentation of Computerized Auditory Training in Chronic Psychosis: Preliminary Findings From a Single-Site, Double-Blind Study.Schizophrenia bulletin · 2025Trial
- Memantine effects on auditory discrimination and training in schizophrenia patients.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Trial
- Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017Trial
- Sensorimotor gating and clinical outcome following cognitive behaviour therapy for psychosis.Schizophrenia research · 2012Trial
- The Relevance of Animal Models of Social Isolation and Social Motivation for Understanding Schizophrenia: Review and Future Directions.Schizophrenia bulletin · 2023Review
- Tics: neurological disorders determined by a deficit in sensorimotor gating processes.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Review
- Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art.Schizophrenia research. Cognition · 2022Review
- Implications from translational cross-validation of clinical assessment tools for diagnosis and treatment in psychiatry.World journal of psychiatry · 2021Review
- Lessons learned by giving amphetamine to antipsychotic-medicated schizophrenia patients.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019Article
- Compensatory Cognitive Training for Latino Youth at Clinical High Risk for Psychosis: Study Protocol for a Randomized Controlled Trial.Frontiers in psychiatry · 2019Article
- Auditory steady state response deficits are associated with symptom severity and poor functioning in patients with psychotic disorder.Schizophrenia research · 2018Article
- Room to move: Plasticity in early auditory information processing and auditory learning in schizophrenia revealed by acute pharmacological challenge.Schizophrenia research · 2018Article
- Amphetamine Enhances Gains in Auditory Discrimination Training in Adult Schizophrenia Patients.Schizophrenia bulletin · 2017Article
- Decreased Left Putamen and Thalamus Volume Correlates with Delusions in First-Episode Schizophrenia Patients.Frontiers in psychiatry · 2017Article
- Longitudinal changes in prospective memory and their clinical correlates at 1-year follow-up in first-episode schizophrenia.PloS one · 2017Article
- Sensorimotor gating of the startle reflex: what we said 25 years ago, what has happened since then, and what comes next.Journal of psychopharmacology (Oxford, England) · 2016Review
- Measuring the capacity for auditory system plasticity: An examination of performance gains during initial exposure to auditory-targeted cognitive training in schizophrenia.Schizophrenia research · 2016Article
- Memantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016Article
- Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia.Annals of the New York Academy of Sciences · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
New findings are rapidly revealing an increasingly detailed image of neural- and molecular-level dysfunction in schizophrenia, distributed throughout interconnected cortico-striato-pallido-thalamic circuitry. Some disturbances appear to reflect failures of early brain maturation, that become codified into dysfunctional circuit properties, resulting in a substantial loss of, or failure to develop, both cells and/or appropriate connectivity across widely dispersed brain regions. These circuit disturbances are variable across individuals with schizophrenia, perhaps reflecting the interaction of multiple different risk genes and epigenetic events. Given these complex and variable hard-wired circuit disturbances, it is worth considering how new and emerging findings can be integrated into actionable treatment models. This paper suggests that future efforts towards developing more effective therapeutic approaches for the schizophrenias should diverge from prevailing models in genetics and molecular neuroscience, and focus instead on a more practical three-part treatment strategy: 1) systematic rehabilitative psychotherapies designed to engage healthy neural systems to compensate for and replace dysfunctional higher circuit elements, used in concert with 2) medications that specifically target cognitive mechanisms engaged by these rehabilitative psychotherapies, and 3) antipsychotic medications that target nodal or convergent circuit points within the limbic-motor interface, to constrain the scope and severity of psychotic exacerbations and thereby facilitate engagement in cognitive rehabilitation. The use of targeted cognitive rehabilitative psychotherapy plus synergistic medication has both common sense and time-tested efficacy with numerous other neuropsychiatric disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.